Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shingrix + Arexvy
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Shingrix + Arexvy is a co-administration regimen of two vaccines developed by GSK. Shingrix is a recombinant subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant, approved for the prevention of shingles. Arexvy is a recombinant subunit vaccine containing the RSV pre-fusion F protein (RSVPreF3) and the AS01E adjuvant, approved for the prevention of respiratory syncytial virus (RSV) infection. The co-administration of these two vaccines is being studied in Phase 3 clinical trials (such as NCT05966090) to evaluate safety and immunogenicity in adults aged 50 and older, aiming to streamline adult immunization schedules and reduce healthcare visits.
- Brand names
- ShingrixArexvy
- Other names
- Recombinant Zoster VaccineRZVRSVPreF3RSVPreF-3RSVPreF 3Respiratory Syncytial Virus Vaccine, Recombinant, Adjuvanted
02
Targets
RSV F (Respiratory syncytial virus fusion protein)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on Shingrix + Arexvy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shingrix + Arexvy.